Researchers have found that an intranasal immunotherapy drug, currently being tested as a treatment for multiple sclerosis, reduced brain inflammation and improved cognition in mice with Alzheimer’s disease, independent of the amount of beta-amyloid plaques present. They say the treatment could benefit people in the later stages of the disease.

Most existing Alzheimer’s treatments focus on the buildup of the beta-amyloid protein plaques common to the disease. Studies have suggested that these plaques trigger the activation of microglia, the brain’s primary immune cells, which leads to inflammation and, ultimately, neuronal dysfunction and death.

See Also:

Sunken Greek Temple Found Off the Coast of Egypt

Researchers from Brigham and Women’s Hospital in the US tested an intranasal monoclonal antibody therapy, currently being tested as a treatment for multiple sclerosis (MS), to see whether it’s effective in reducing the neuroinflammation associated with Alzheimer’s disease.

Continue here: New Atlas